ArticleCancers2018
Comprehensive Analysis of Germline Variants in Mexican Patients with Hereditary Breast and Ovarian Cancer Susceptibility.
Open access · goldAbstract read
In one paragraph
Article in Cancers, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 9% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Summary ofGenes · 2020Pooled it
- Cancer spectrum in Mexican patients with the CHEK2 p.(Leu236Pro) variant: a retrospective study.Familial cancer · 2025Article
- Los olvidados: Non-BRCA variants associated with Hereditary breast cancer in Mexican population.Breast cancer research : BCR · 2025Article
- Cancer genomics and bioinformatics in Latin American countries: applications, challenges, and perspectives.Frontiers in oncology · 2025Review
- Methylation marks in blood DNA reveal breast cancer risk in patients fulfilling hereditary disease criteria.NPJ precision oncology · 2024Article
- Evaluation of genetic alterations in hereditary cancer susceptibility genes in the Ashkenazi Jewish women community of Mexico.Frontiers in genetics · 2023Article
- Review
- Article
- Homologous Recombination Deficiency in Ovarian, Breast, Colorectal, Pancreatic, Non-Small Cell Lung and Prostate Cancers, and the Mechanisms of Resistance to PARP Inhibitors.Frontiers in oncology · 2022Review
- Clinical Benefits of Olaparib in Mexican Ovarian Cancer Patients With Founder MutationFrontiers in genetics · 2022Article
- Genetic epidemiology of BRCA1- and BRCA2-associated cancer across Latin America.NPJ breast cancer · 2021Article
- Germline variants in DNA repair genes associated with hereditary breast and ovarian cancer syndrome: analysis of a 21 gene panel in the Brazilian population.BMC medical genomics · 2020Article
- Identifying sequence variants contributing to hereditary breast and ovarian cancer in BRCA1 and BRCA2 negative breast and ovarian cancer patients.Scientific reports · 2019Article
- Review
- Review
- Enrichment of heterozygous germlineCold Spring Harbor molecular case studies · 2019Article
- Mexican BRCA1 founder mutation: Shortening the gap in genetic assessment for hereditary breast and ovarian cancer patients.PloS one · 2019Article
- Andrographolide as a Therapeutic Agent Against Breast and Ovarian Cancers.Open life sciences · 2019Article
- Latin American Study of Hereditary Breast and Ovarian CancerFrontiers in oncology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
32 authors at 10 institutions in 4 countries.
Rosalía Quezada UrbanLaboratorio Nacional en Salud, Diagnóstico Molecular y Efecto Ambiental en Enfermedades Crónico-Degenerativas, Facultad de Estudios Superiores Iztacala, Tlalnepantla, Estado de México 54090, Mexico. rosieurban@hotmail.com.
Clara Estela Díaz VelásquezLaboratorio Nacional en Salud, Diagnóstico Molecular y Efecto Ambiental en Enfermedades Crónico-Degenerativas, Facultad de Estudios Superiores Iztacala, Tlalnepantla, Estado de México 54090, Mexico. cdiazvelasquez@aol.com.
Rina GitlerFundación Alma, CDMX 11560, Mexico. direccion@alma.org.mx.
María Patricia Rojo CastilloFundación Alma, CDMX 11560, Mexico. mpatrojoc@gmail.com.
Max Sirota ToporekFundación Alma, CDMX 11560, Mexico. maxsir89@gmail.com.
Andrea Figueroa MoralesFundación Alma, CDMX 11560, Mexico. eidna.92@gmail.com.
Oscar Moreno GarcíaFundación Alma, CDMX 11560, Mexico. ojmor10@gmail.com.
Lizbeth García EsquivelFundación Alma, CDMX 11560, Mexico. liz.gaes@gmail.com.
Gabriela Torres MejíaInstituto Nacional de Salud Pública, 62100 Cuernavaca, Morelos, Mexico. gtorres@insp.mx.
Michael DeanDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD 20892, USA. deanm@mail.nih.gov.ORCID 0000-0003-2234-0631
Iván Delgado EncisoInstituto Estatal de Cancerología de Colima, Colima 28000, Colima, Mexico. ivancoliman@hotmail.com.ORCID 0000-0001-9848-862X
Héctor Ochoa Díaz LópezDepartment of Health, El Colegio de la Frontera Sur (ECOSUR), San Cristóbal de Las Casas 29290, Chiapas, Mexico. hochoa@ecosur.mx.
Fernando Rodríguez LeónDepartment of Health, El Colegio de la Frontera Sur (ECOSUR), San Cristóbal de Las Casas 29290, Chiapas, Mexico. ferrodleon@hotmail.com.
Virginia JanInternal Medicine, Hospital de Especialidades Vida Mejor, ISSTECH, Tuxtla Gutiérrez 29040, Chiapas, Mexico. viky_jan@hotmail.com.
Víctor Hugo Garzón BarrientosHospital General de Chilpancingo, Chilpancingo de los Bravo 39019, Guerrero, Mexico. victhorgb@gmail.com.
Pablo Ruiz FloresCentro de Investigación Biomédica, Universidad Autónoma de Coahuila, Torreón 27000, Coahuila, Mexico. pabloruiz1047@gmail.com.ORCID 0000-0003-0187-1468
Perla Karina Espino SilvaCentro de Investigación Biomédica, Universidad Autónoma de Coahuila, Torreón 27000, Coahuila, Mexico. pekaessi@hotmail.com.ORCID 0000-0003-1524-8431
Jorge Haro Santa CruzCentro de Investigación Biomédica, Universidad Autónoma de Coahuila, Torreón 27000, Coahuila, Mexico. qfbharosanta@gmail.com.ORCID 0000-0002-3635-886X
Héctor Martínez GregorioLaboratorio Nacional en Salud, Diagnóstico Molecular y Efecto Ambiental en Enfermedades Crónico-Degenerativas, Facultad de Estudios Superiores Iztacala, Tlalnepantla, Estado de México 54090, Mexico. mag_hector@hotmail.com.
Ernesto Arturo Rojas JiménezLaboratorio Nacional en Salud, Diagnóstico Molecular y Efecto Ambiental en Enfermedades Crónico-Degenerativas, Facultad de Estudios Superiores Iztacala, Tlalnepantla, Estado de México 54090, Mexico. erarroji@gmail.com.
Luis Enrique Romero CruzLaboratorio Nacional en Salud, Diagnóstico Molecular y Efecto Ambiental en Enfermedades Crónico-Degenerativas, Facultad de Estudios Superiores Iztacala, Tlalnepantla, Estado de México 54090, Mexico. k.ikeo3@comunidad.unam.mx.
Claudia Fabiola Méndez CataláLaboratorio Nacional en Salud, Diagnóstico Molecular y Efecto Ambiental en Enfermedades Crónico-Degenerativas, Facultad de Estudios Superiores Iztacala, Tlalnepantla, Estado de México 54090, Mexico. mendezcatalacf@gmail.com.
Rosa María Álvarez GómezInstituto Nacional de Cancerología, CDMX 14080, Mexico. rosamag2@hotmail.com.
Verónica Fragoso OntiverosInstituto Nacional de Cancerología, CDMX 14080, Mexico. ontiverosfvero@yahoo.com.mx.
Luis Alonso HerreraUnidad de Investigación Biomédica en Cáncer, Instituto de Investigaciones Biomédicas-Instituto Nacional de Cancerología, CDMX 14080, Mexico. metil@hotmail.com.
Isabelle RomieuCenter for Center for Research on Population Health, National Institute of Public Health, Cuernavaca 62100, Morelos, Mexico. iromieu@gmail.com.
Luis Ignacio TerrazasLaboratorio Nacional en Salud, Diagnóstico Molecular y Efecto Ambiental en Enfermedades Crónico-Degenerativas, Facultad de Estudios Superiores Iztacala, Tlalnepantla, Estado de México 54090, Mexico. literrazas@unam.mx.
Yolanda Irasema ChirinoLaboratorio Nacional en Salud, Diagnóstico Molecular y Efecto Ambiental en Enfermedades Crónico-Degenerativas, Facultad de Estudios Superiores Iztacala, Tlalnepantla, Estado de México 54090, Mexico. irasemachirino@gmail.com.
Cecilia FrechaHospital Italiano, Buenos Aires C1199ABB, Argentina. frechacecilia@gmail.com.
Javier OliverHospital Italiano, Buenos Aires C1199ABB, Argentina. javiom@gmail.com.ORCID 0000-0002-8073-4711
Sandra PerdomoInvestigación en Nutrición, Genética y Metabolismo, Facultad de Medicina, Universidad El Bosque, Bogotá 110121, Colombia. perdomosandra@unbosque.edu.co.ORCID 0000-0001-7740-8141
Felipe Vaca PaniaguaLaboratorio Nacional en Salud, Diagnóstico Molecular y Efecto Ambiental en Enfermedades Crónico-Degenerativas, Facultad de Estudios Superiores Iztacala, Tlalnepantla, Estado de México 54090, Mexico. felipe.vaca@gmail.com.ORCID 0000-0002-2200-9706
Instituto Nacional de Cancerología · MXUniversidad Autónoma de Coahuila · MXEl Colegio de la Frontera Sur · MXHospital Italiano de Buenos Aires · AREmory University · USHospital de Especialidades · MXInstituto Nacional de Salud Pública · MXNational Cancer Institute · USUniversidad de Colima · MXUniversidad El Bosque · CO
Funding
Consejo Nacional de Ciencia y Tecnología 264410Consejo Nacional de Ciencia y Tecnología 271685Consejo Nacional de Ciencia y Tecnología 285879Universidad Nacional Autónoma de México IA204215
Abstract
Hereditary breast and ovarian cancer syndrome (HBOC) represents 5⁻10% of all patients with breast cancer and is associated with high-risk pathogenic alleles in
Indexed as
BRCA1/2gene panelgenetic screeninghereditary breast cancermassive parallel sequencingpathogenic variants
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.